BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma Inc.

Analysts are intrested in these 5 stocks: ( ($LDOS) ), ( ($BBIO) ), ( ($TE) ), ( ($EC) ) and ( ($MDT) ). Here is a breakdown of their recent


Leidos, BridgeBio, T1 Energy, Ecopetrol, Medtronic Trending

In a report released today, Eliana Merle from Barclays maintained a Buy rating on BridgeBio Pharma, with a price target of $157.00. Merle covers th...

Barclays Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tempus AI, Inc. Class A (TEM), Tyra Bioscience (TY...

Analysts Conflicted on These Healthcare Names: Tempus AI, Inc. Class A (TEM), Tyra Bioscience (TYRA) and BridgeBio Pharma (BBIO)

Analysts are intrested in these 5 stocks: ( ($BBIO) ), ( ($DAVE) ), ( ($MRVL) ), ( ($FLNA) ) and ( ($GE) ). Here is a breakdown of their recent


BridgeBio, Dave, Marvell, Filana, GE Trending With Analysts

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY) and BridgeBio Pharma (BBI...

Analysts Are Bullish on These Healthcare Stocks: Bristol-Myers Squibb (BMY), BridgeBio Pharma (BBIO)

BridgeBio Pharma received a Hold rating and price target from Citi analyst today. In addition to Citi, BridgeBio Pharma also received a Hold from J...

BridgeBio Pharma (BBIO) Gets a Hold from Citi

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cardiol Therapeutics (CRDL) and BridgeBio Pharma (BB...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BBIO	$67.90	+0.43%	199.20K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BBIO	$67.90	+0.4%	199.20K
3
4
5
6

BBIO

BBIO

Dividend Overview

Get BridgeBio Pharma Inc. Data in Excel

Get BridgeBio Pharma Inc. Data in Excel